AR121881A1 - Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos - Google Patents

Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos

Info

Publication number
AR121881A1
AR121881A1 ARP210101045A ARP210101045A AR121881A1 AR 121881 A1 AR121881 A1 AR 121881A1 AR P210101045 A ARP210101045 A AR P210101045A AR P210101045 A ARP210101045 A AR P210101045A AR 121881 A1 AR121881 A1 AR 121881A1
Authority
AR
Argentina
Prior art keywords
antibodies
factor
complement
humanized anti
methods
Prior art date
Application number
ARP210101045A
Other languages
English (en)
Inventor
Graham Parry
Stephen Moore
Michael Storek
Nina C Leksa
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR121881A1 publication Critical patent/AR121881A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En la presente se proporcionan anticuerpos humanizados anti-factor Bb, métodos de producción de los anticuerpos y métodos de utilización de los anticuerpos.
ARP210101045A 2020-04-20 2021-04-19 Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos AR121881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063012590P 2020-04-20 2020-04-20

Publications (1)

Publication Number Publication Date
AR121881A1 true AR121881A1 (es) 2022-07-20

Family

ID=78221896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101045A AR121881A1 (es) 2020-04-20 2021-04-19 Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos

Country Status (14)

Country Link
US (2) US11242382B2 (es)
EP (1) EP4139350A4 (es)
JP (1) JP2023522102A (es)
KR (1) KR20230004686A (es)
CN (1) CN115702165A (es)
AR (1) AR121881A1 (es)
AU (1) AU2021261257A1 (es)
BR (1) BR112022021077A2 (es)
CA (1) CA3173325A1 (es)
CO (1) CO2022014878A2 (es)
IL (1) IL297444A (es)
MX (1) MX2022013135A (es)
TW (1) TW202140543A (es)
WO (1) WO2021216458A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL262010B (en) 2016-04-04 2022-09-01 Bioverativ Usa Inc Anti-complement factor bb antibodies and their uses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2885854C (en) * 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
ES2526079T3 (es) 2005-12-20 2015-01-05 Sbi Biotech Co., Ltd. Anticuerpo anti-ILT7
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
WO2013063395A1 (en) * 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
AU2013243570B2 (en) 2012-04-03 2017-12-14 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CN114591433A (zh) * 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
IL262010B (en) 2016-04-04 2022-09-01 Bioverativ Usa Inc Anti-complement factor bb antibodies and their uses
PE20191031A1 (es) * 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法

Also Published As

Publication number Publication date
BR112022021077A2 (pt) 2022-12-13
CA3173325A1 (en) 2021-10-28
KR20230004686A (ko) 2023-01-06
IL297444A (en) 2022-12-01
US20210332115A1 (en) 2021-10-28
US11242382B2 (en) 2022-02-08
EP4139350A4 (en) 2024-04-24
EP4139350A1 (en) 2023-03-01
TW202140543A (zh) 2021-11-01
AU2021261257A1 (en) 2022-12-22
US20220213179A1 (en) 2022-07-07
JP2023522102A (ja) 2023-05-26
MX2022013135A (es) 2022-11-10
CN115702165A (zh) 2023-02-14
WO2021216458A1 (en) 2021-10-28
CO2022014878A2 (es) 2023-02-16

Similar Documents

Publication Publication Date Title
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
CL2018003565A1 (es) Anticuerpos antifactor de la coagulación xi.
BR112022000876A2 (pt) Anticorpos imunomoduladores e métodos de uso destes
PE20201343A1 (es) Anticuerpos anti-trem-1 y usos de los mismos
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2021000660A2 (es) Receptores químericos de steap1 y métodos de uso de los mismos
AR121881A1 (es) Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
GT201700088A (es) Mezcla paramétrica de señales de audio
EA201990270A1 (ru) Смеси, содержащие defi и тауратамиды, и способы их получения
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
EA201892442A1 (ru) Конструкция